Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
8 March 2021 |
Main ID: |
EUCTR2014-003731-20-ES |
Date of registration:
|
09/01/2015 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult patients with cMet positive non-small cell lung cancer
|
Scientific title:
|
A phase II, multicenter, open-label study of EGF816 in combination with Nivolumab in adult patients with EGFR mutated non-small cell lung cancer and of INC280 in combination with Nivolumab in adult patients with cMet positive non-small cell lung cancer |
Date of first enrolment:
|
19/06/2015 |
Target sample size:
|
100 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2014-003731-20 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: no
Randomised: no
Open: yes
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
Number of treatment arms in the trial: 2
|
Phase:
|
Human pharmacology (Phase I): no
Therapeutic exploratory (Phase II): yes
Therapeutic confirmatory - (Phase III): no
Therapeutic use (Phase IV): no
|
|
Countries of recruitment
|
Australia
|
Canada
|
France
|
Germany
|
Italy
|
Netherlands
|
Norway
|
Singapore
|
Spain
|
Switzerland
|
United States
| | | | | |
Contacts
|
Name:
|
Departamento Médico Oncología (GMO)
|
Address:
|
Gran Vía de les Corts Catalanes, 764
08013
Barcelona
Spain |
Telephone:
|
34900353036 |
Email:
|
eecc.novartis@novartis.com |
Affiliation:
|
Novartis Farmacéutica, S.A. |
|
Name:
|
Departamento Médico Oncología (GMO)
|
Address:
|
Gran Vía de les Corts Catalanes, 764
08013
Barcelona
Spain |
Telephone:
|
34900353036 |
Email:
|
eecc.novartis@novartis.com |
Affiliation:
|
Novartis Farmacéutica, S.A. |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: ? Advanced metastatic and/or unresectable NSCLC ? Measurable disease as determined by RECIST version 1.1 ? ECOG performance ?2 ? Patients in Group 1: confirmed T790M EGFR mutation ? Patients in Group 2: confirmed c-MET positive
Other inclusion criteria may apply as per protocol Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 50 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 50
Exclusion criteria: ? For Group 1: Patients who have received more than one prior line of EGFR TKI therapy ? For Group 2: Previous treatment with a c-MET inhibitor or HGF-targeting therapy ? Prior treatment with PD1/PD-L1 targeting therapies ? Subjects who require emergent use of systemic steroids, emergent surgery and/or radiotherapy ? Patients with interstitial lung disease ? Patients with any active or history of autoimmune disease
Other exclusion criteria may apply as per protocol
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
EGFR mutated non-small cell lung cancer and cMet positive non-small cell lung cancer MedDRA version: 17.1
Level: LLT
Classification code 10025044
Term: Lung cancer
System Organ Class: 100000004864
|
Therapeutic area: Diseases [C] - Cancer [C04]
|
Intervention(s)
|
Product Code: INC280 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: not applicable CAS Number: 1197376-85-4 Current Sponsor code: INC280 Other descriptive name: INC280 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 200-
Product Code: INC280 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: not applicable CAS Number: 1197376-85-4 Current Sponsor code: INC280 Other descriptive name: INC280 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-
Product Code: EGF816 Pharmaceutical Form: Capsule, hard INN or Proposed INN: not applicable CAS Number: EGF816 Current Sponsor code: EGF816 Other descriptive name: EGF816 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 25-
Product Code: EGF816 Pharmaceutical Form: Capsule, hard INN or Proposed INN: not applicable CAS Number: EGF816 Current Sponsor code: EGF816 Other descriptive name: EGF816 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 50-
Product Code: EGF816 Pharmaceutical Form: Capsule, hard INN or Proposed INN: not applicable CAS Number: EGF816 Current Sponsor code: EGF816 Other descriptive name: EGF816 Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 100-
Product Name: nivolumab Product Code: BMS-936558 Pharmaceutical Form: Solution for injection/infusion INN or Proposed INN: nivolumab CAS Number: 946414-94-4 Current Sponsor code: BMS-936558-01 Other descriptive name: BMS936558 Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal Concentration number: 10-
Product Code: INC280 Pharmaceutical Form: Film-coated tablet INN or Proposed INN: not applicable CAS Number: 1197376-85-4 Current Sponsor code: I
|
Primary Outcome(s)
|
Secondary Objective: 1. To evaluate the preliminary antitumor activity of EGF816 and Nivolumab and of INC280 and Nivolumab 2. To characterize the safety and tolerability of EGF816 and Nivolumab or of INC280 and Nivolumab 3. To evaluate PK of EGF816, INC280 and Nivolumab in the combination setting
|
Primary end point(s): PFS rate using RECIST version1.1
|
Timepoint(s) of evaluation of this end point: 6 month
|
Main Objective: To estimate the clinical activity of Nivolumab in combination with EGF816 or INC280
|
Secondary Outcome(s)
|
Secondary end point(s): 1. ORR, DCR, other PFS measures, OS 2. Safety, incidence of AEs and SAEs, including changes in hematology and chemistry values, vital signs and ECGs Tolerability: Dose interruptions, reductions, and dose intensity 3. PK parameters of Nivolumab,EGF816 and INC280 such as Cmax, AUC and Cmin
|
Timepoint(s) of evaluation of this end point: 1. ORR, DCR, PFS : 3 month OS: 1 year
2. Please refer to table 7.1 of the protocol
3. EGF816 and INC280 (safety monitoring cohort): D1,8,15 cycle 1, D1 cycle 2 then on D1 cycles 4,6,8 EGF816 and INC280 (after safety monitoring cohort): D15 cycle 1, D1 cycle 2 then on D1 cycles 4,6,8 Nivolumab (all patients): D15 cycle 1, D1 cycle 2 then on D1 cycles 4, 6, 8 then every 8th cycle after cycle 8 D1.
|
Secondary ID(s)
|
2014-003731-20-DE
|
CEGF816X2201C
|
Source(s) of Monetary Support
|
Novartis Pharma Services AG
|
Ethics review
|
Status: Approved
Approval date: 05/02/2015
Contact:
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|